...
首页> 外文期刊>Journal of Medicinal Chemistry >Development of Natural Product-Derived Receptor Tyrosine Kinase Inhibitors Based on Conservation of Protein Domain Fold
【24h】

Development of Natural Product-Derived Receptor Tyrosine Kinase Inhibitors Based on Conservation of Protein Domain Fold

机译:基于蛋白质结构域折叠保守性的天然产物受体酪氨酸激酶抑制剂的开发

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Receptor tyrosine kinases (RTKs) such as Tie-2, IGF1R, Her-2/Neu, EGFR, and VEGFR1-3 play crucial roles in the control of cell growth and differentiation. Inhibition of such RTKs has become a major focus of current anticancer drug development, and therefore the discovery of new classes of inhibitors for these signal-transducing proteins is of prime importance. We have recently proposed a novel concept for improving the hit-finding process by employing natural products as biologically validated starting points in structural space for compound library development. In this concept, natural products are regarded as evolutionary chosen ligands for protein domains which are structurally conserved yet genetically mobile. Here we report on the discovery of novel and highly selective VEGFR-2 and -3, Tie-2, and IGF1R inhibitors derived from the naturally occurring Her-2/Neu kinase inhibitor nakijiquinone C and developed on the basis of this concept. Based on the structure of the natural product, a small library (74 members) was synthesized and investigated for inhibition of kinases with highly similar ATP-binding domains. The library yielded inhibitors with IC_(50)s in the low micromolar range with high frequency (7 out of 74). In particular, four inhibitors of Tie-2 were found, a kinase critically involved in the formation of new blood vessels from preexisting ones (angiogenesis) and believed to be a new promising target in antitumor therapy. These results support the "domain concept". To advance the development of improved inhibitors, extensive molecular modeling studies were undertaken, including the construction of new homology models for VEGFR-2 and Tie-2. These studies revealed residues in the kinase structure which are crucial to the development of tailormade receptor tyrosine kinase inhibitors.
机译:受体酪氨酸激酶(RTK),例如Tie-2,IGF1R,Her-2 / Neu,EGFR和VEGFR1-3在控制细胞生长和分化中起关键作用。抑制此类RTK已成为当前抗癌药物开发的主要重点,因此,发现针对这些信号转导蛋白的新型抑制剂至关重要。我们最近提出了一种新颖的概念,可通过将天然产物用作化合物库开发的结构空间中经过生物学验证的起点来改善命中查找过程。在这个概念中,天然产物被认为是蛋白质结构域的进化选择配体,其在结构上是保守的但在遗传上是可移动的。在这里,我们报道了从天然存在的Her-2 / Neu激酶抑制剂nakijiquinone C衍生并基于此概念开发的新型且高度选择性的VEGFR-2和-3,Tie-2和IGF1R抑制剂的发现。基于天然产物的结构,合成了一个小型文库(74个成员),并研究了其对具有高度相似的ATP结合域的激酶的抑制作用。该文库产生了IC_(50)s在低微摩尔范围内且具有较高频率的抑制剂(74种中的7种)。尤其是,发现了四种Tie-2抑制剂,这是一种从先前存在的新血管形成至关重要的激酶(血管生成),被认为是抗肿瘤治疗的新靶标。这些结果支持“领域概念”。为了促进改进抑制剂的开发,进行了广泛的分子建模研究,包括构建VEGFR-2和Tie-2的新同源性模型。这些研究揭示了激酶结构中的残基,这些残基对于开发定制受体酪氨酸激酶抑制剂至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号